__NUXT_JSONP__("/drugs/Ningetinib_Tosylate", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"The tosylate salt form of ningetinib, an orally available inhibitor of the receptor tyrosine kinases c-MET\u002Fhepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor 2 (VEGFR2 KDR), Axl (UFO), Mer, and Fms-like tyrosine kinase 3 (Flt3; CD135; STK1; FLK2), with antineoplastic activity. Upon administration, ningetinib binds to a variety of kinases, including c-Met, VEGFR2, Axl, Mer and Flt3, thereby inhibiting their signaling pathways. This inhibits growth, angiogenesis and metastasis of tumor cells that overexpress these kinases. c-Met, VEGFR2, Axl, Mer and Flt3 are overexpressed by many tumor cell types and play key roles in tumor cell proliferation, survival, invasion and metastasis.",fdaUniiCode:"R7I5725FES",identifier:"C148529",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C1967"],synonyms:["CT-053 Tosylate","CT-053-PTSA","CT-053PTSA","NINGETINIB TOSYLATE",c]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FNingetinib_Tosylate",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Ningetinib_Tosylate","Ningetinib Tosylate","2021-10-30T13:33:14.823Z")));